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Autism spectrum disorder (ASD) is a neurological disorder in which a significant number of children experience a
developmental regression characterized by a loss of previously-acquired skills and abilities. Loss of neurological function
in ASD, as observed in affected children who have regressed, can be explained as neurodegeneration. Although there
is research evidence of neurodegeneration or progressive encephalopathy in ASD, the issue of neurodegeneration in
ASD is still under debate. Evidence of neurodegeneration in the brain in ASD includes: (1) neuronal cell loss, (2)
activated microglia and astrocytes, (3) proinflammatory cytokines, (4) oxidative stress, and (5) elevated 8-oxo-guanosine
levels. The evidence from this review suggests that neurodegeneration underlies the loss of neurological function in
children with ASD who have experienced regression and loss of previously acquired skills and abilities, and that
research into treatments to address the issue of neurodegeneration in ASD are warranted.
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The Diagnostic and Statistical Manual of Mental Disorders,
5th Revision (DSM-V) defines autism spectrum disorder
(ASD) as a neurological disorder with a spectrum of quali-
tative impairments in social interaction, qualitative impair-
ments in communication, and restricted and stereotyped
patterns of behavior, interests, and activities [1]. ASD diag-
noses disproportionately affect males (about 4–5 males per
1 female) and usually manifest in children before the age of
3 years [2,3]. Individuals diagnosed with an ASD are unable
to learn from the natural environment in ways similar to
neurotypical children. Most individuals diagnosed with an
ASD show little interest in the world or people around
them, and have a lifelong disability that affects the way a
person comprehends, communicates, and relates to others.
In addition, a recent study revealed individuals diagnosed
with an ASD have a high prevalence of gastrointestinal dis-
turbances, incontinence, sleep problems, eating disorders,
hyperactivity, lethargy, sensory processing problems, anx-
iety/fear, behavior problems, and obsessive-compulsive be-
haviors [2]. Over the past two decades, the prevalence of* Correspondence: jkern@dfwair.net
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reproduction in any medium, provided the orindividuals diagnosed with an ASD has risen dramatically
[4]. Currently, at least 1 in 50 children are diagnosed with
an ASD in the United States [5].Regression in ASD
In the context of neurodegeneration, the regression ex-
perienced by a significant number of children diagnosed
with ASD who suffer a loss of previously-acquired skills
is of particular interest [6-8]. Typically, regression in
children diagnosed with an ASD is manifested by a loss
of verbal, nonverbal, and social abilities [7-10]. The
reported incidence of regression in individuals diagnosed
with an ASD varies in different studies from 15% to 62%
of cases [6,7,9,11,12].
Several studies have been undertaken to objectively
evaluate the phenomenon of autistic regression early in
life. For example, Werner and Dawson [13] evaluated
home videotapes of children between their first and sec-
ond birthday parties, including children diagnosed with an
ASD, both with and without a reported history of regres-
sion, as well as typically developing children. Analyses re-
vealed that infants diagnosed with an ASD with regression
show similar use of joint attention and more frequent use
of words and babble, compared with typical infants at 12
months of age. In contrast, infants diagnosed with an ASDd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fewer joint attention and communicative behaviors at 12
months of age. By 24 months of age, both groups of tod-
dlers diagnosed with an ASD displayed fewer instances of
word use, vocalizations, declarative pointing, social gaze,
and orienting to name as compared with typically develop-
ing 24-month-olds.
Similarly, Ozonoff et al [14] evaluated the emergence of
the early behavioral signs of an ASD diagnosis, including
gaze to faces, social smiles, and directed vocalization
coded from video and rated by examiners, by evaluating
study subjects at 6, 12, 18, 24, and 36 months of age in a
prospective longitudinal study. These investigators ob-
served that the frequency of infant gaze directed to faces,
shared smiles, and vocalizations to others were highly
comparable between groups at 6 months of age, but these
trajectories significantly declined over time in the group
later diagnosed with an ASD. Group differences were sig-
nificant by 12 months of age on most variables. These in-
vestigators concluded that their results suggest behavioral
signs of ASD are not present at birth, as suggested histor-
ically by Kanner, but instead emerge over time through a
process of diminishment affecting key social communica-
tion behaviors. Their results also suggest that more chil-
dren with ASD may present with a regressive course than
previously thought.
Debate of neurodegeneration in ASD
Loss of neurological function in ASD, as observed in af-
fected children who have regressed, can be explained as
neurodegeneration or a type of progressive encephalop-
athy. Neurodegeneration is the progressive loss of struc-
ture or function of neurons. In diseases that are classically
known as neurodegenerative, such as Parkinson’s disease
(PD), Alzheimer’s disease (AD), or Huntington’s disease,
early clinical symptoms manifest as neurological loss,
which is also noted in children diagnosed with an ASD
who have regressed. Courchesne et al [15] observed that
there is evidence of progressive, age-related degeneration
in the brains of individual diagnosed with an ASD. How-
ever, others have suggested that there is no evidence in
autism of neurodegeneration [16]. Thus, to date, the issue
remains under debate. The purpose of the present critical
review is to provide an overview of the recent literature in
neuroscience that provides important new insights into
the phenomena of neurodegeneration in ASD.
Neuronal cell loss and neurodegeneration
Many studies suggest ASD is characterized by neuronal
cell loss [15]. At least seven post-mortem studies reported
significant reductions in the number of cerebellar Purkinje
cells (PCs) in the brains of individuals diagnosed with an
ASD [17-23]. For example, Ritvo et al [23] found that the
number of PCs in the vermis of the cerebellum wereapproximately 15 standard deviations below the mean and
approximately 8 standard deviations below the mean bilat-
erally in the cerebellar hemispheres, in the individuals di-
agnosed with an ASD in comparison to neurotypical
controls. According to a postmortem study by Whitney et
al [24] PCs were generated, migrated to their proper loca-
tion in the PC layer but subsequently died.
Other studies demonstrate that the neuronal pathology
found in the brain of individuals diagnosed with an ASD is
suggestive of a neurodegenerative process. After examining
the brains of individuals diagnosed with an ASD, Vargas et
al [22] reported degeneration in PCs and also microglial ac-
tivation (microglial activation will be discussed further in
the next section). Bailey et al [20] reported the PC loss was
associated with gliosis, indicating that these changes are ac-
quired rather than neurodevelopmental in nature [25]
[Gliosis is proliferation of neuroglial tissue that follows
neural damage] [26].
Other studies have also observed that fewer neurons are
found in other areas of the brain in individuals diagnosed
with an ASD when compared to neurotypical subjects.
Neuronal numbers were found to be fewer in the amygdala
of individuals diagnosed with an ASD than controls [27].
Other investigators observed that neurons in the fusiform
gyrus were also fewer (and smaller) in individuals diagnosed
with an ASD as compared to controls. Specifically, these
significant reductions in neuron densities were found in
layer III, total neuron numbers in layers III, V and VI, and
mean perikaryal volumes of neurons in layers V and VI in
the fusiform gyrus [28]. Postmortem studies also show
fewer pyramidal cells in the brains of individuals diagnosed
with an ASD when compared to controls [29].
Microglia activation and neurodegeneration
Microglial reactivity is commonly noted in neurodegenera-
tive diseases [30]. Microglia, a type of glial cell, are the resi-
dent tissue macrophage of the central nervous system
(CNS). Microglia promote inflammation in infected or
damaged tissue and are important for maintaining homeo-
stasis in non-infected regions [30]. Microglia act as key cel-
lular mediators of the neuroinflammatory processes and are
associated with the pathogenesis of many neurodegenera-
tive and brain inflammatory diseases and disorders, such as
AD, PD, stroke, spinal cord injury, encephalitis, and mul-
tiple sclerosis (MS) [30,31].
Although the role of microglia in neurodegeneration is
not entirely understood, evidence indicates that micro-
glia can become transiently activated to an amoeboid
phenotype responsible for the phagocytosis of living
neurons [32,33]. In addition, particularly in long-term
neuroimmune activation, microglia produce cytokines
that are toxic to neurons, and this neurotoxicity plays a
potential role in neurodegeneration [34]. With sustained
microglial activation, collateral neural damage of healthy
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Nam et al [36] found (using a model of mitochondrial
membrane potential loss) there was only 25% cell loss in
SH-SY5Y (SH) neuronal mono-cultures, but that 85% neur-
onal loss occurred when neurons were co-cultured with
BV2 microglia. These investigators reported that SH neu-
rons overexpressing uncoupling protein 2 exhibited an in-
crease in neuron-microglia interactions, which represented
an early step in microglial phagocytosis of neurons.
Sometimes neurodegeneration involves degeneration of
presynaptic terminals prior to the loss of the cell body.
There is some debate as to the involvement of microglia
in synaptic stripping and synapse degeneration [37].
Numerous recent studies provide evidence that indi-
viduals diagnosed with an ASD suffer from an ongoing
neuroinflammatory process in different regions of the
brain involving microglial activation [22,38-43]. Evidence
from post-mortem brain tissue documents activated
microglia and astrocytes [22,38,39].
Vargas et al [22] observed that among the brain re-
gions studied, the cerebellum showed the most neuro-
glial responses in individuals diagnosed with an ASD.
They stated that the selective process of neuronal degen-
eration and neuroglial activation appears to occur pre-
dominantly in the PC layer and the granular cell layer of
cerebellum and that these findings are consistent with
an active and ongoing postnatal process of neurode-
generation and neuroinflammation. They also stated
that the proinflammatory chemokine, monocyte chemo-
tactic protein-1 (MCP-1), was consistently elevated in the
brain regions studied in individuals diagnosed with an
ASD, and that increased expression of MCP-1 may have
relevance to the pathogenesis of ASD because its elevation
in the brain is linked to microglial activation, and perhaps,
to the recruitment of monocytes/macrophages to areas of
neurodegeneration in the cerebellum. Importantly, these
investigators concluded that their observations are similar
to findings in other neurodegenerative diseases in which
elevation of MCP-1 is associated, such as human immuno-
deficiency virus (HIV) dementia, amyotrophic lateral scle-
rosis (ALS), and multiple sclerosis (MS).
Microglial activation is found in the cerebrum as well
as the cerebellum of individuals diagnosed with an ASD.
Tetreault et al [43] immunocytochemically identified
microglia and stereologically quantified microglial dens-
ities in the fronto-insular and visual cortex from autop-
sies of the brain in individuals diagnosed with an ASD in
comparison to matched controls. They observed in-
creased densities of microglia in both cortical areas in
the brains of individuals diagnosed with an ASD as com-
pared to controls. Suzuki et al [42] used positron emis-
sion tomography (PET) and a radiotracer for microglia
to identify brain regions associated with excessively
activated microglia in the whole brain, in individualsdiagnosed with an ASD as compared to controls. They
determined that increased microglial activation was
present in the: cerebellum, midbrain, pons, fusiform gyri,
and the anterior cingulate and orbitofrontal cortices, in in-
dividuals diagnosed with an ASD in comparison to con-
trols. The investigators also observed, in accord with the
observations made by Vargas et al [22], that the area with
the most prominent increase was the cerebellum in indi-
viduals diagnosed with an ASD in comparison to controls.
Proinflammatory cytokines and neurodegeneration
Activated microglia can release a number of potentially
neurotoxic substances, such as reactive oxygen species,
nitric oxide, and various proinflammatory cytokines, and
evidence implicates neuroinflammation and overproduc-
tion of proinflammatory cytokines as a contributor to
pathophysiology of chronic neurodegenerative disorders
[44]. Proinflammatory cytokines are found in chronic
neurodegenerative disorders such as AD, PD, and MS.
Studies show elevated proinflammatory cytokines in the
brains and spinal cords of individuals diagnosed with an
ASD. Li et al [45], for example, showed that proinflam-
matory cytokines (tumor necrosis factor (TNF)-α, in-
terleukin (IL)-6 and granulocyte-macrophage colony-
stimulating factor (GM-CSF), Th1 cytokine (interferon
(IFN)-γ) and chemokine (IL-8) were significantly in-
creased in the brains of individuals diagnosed with an
ASD compared with controls. A study by Vargas et al
[22] demonstrated tumor growth factor-β1, derived
from neuroglia, was significantly increased in the mid-
dle frontal gurus (MFG) of individuals diagnosed with
an ASD, while MCP-1, IL-6 and IL-10 were increased in
the anterior cingulated gurus (ACG), in comparison to
controls. In addition, using a protein array approach,
Vargas et al [22] also found that MCP-1, IL-6, IL-8 and
IFN-γ were significantly increased in the cerebrospinal
fluid (CSF) in individuals diagnosed with an ASD in
comparison to controls. Chez et al [46] also observed
that there was a significant increase in TNF-α in the
CSF of individuals diagnosed was an ASD in compari-
son to the concurrent serum levels and that the magni-
tude of the difference was significantly higher than that
observed for other diseases.
Oxidative stress and neurodegeneration
Over production of reactive oxygen species (ROS) or oxida-
tive stress is a central feature of neurodegenerative disor-
ders [47]. Postmortem brain tissues from individuals
diagnosed with neurodegenerative disorders, including PD,
AD and ALS, display increased levels of ROS in affected
brain regions [48].
Free radicals and other ROS are produced in all species.
Any free radical involving oxygen can be referred to as ROS,
e.g. nitric oxide (NO). Free radicals and other ROS are
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They are harmful because the unpaired electron oxidatively
reacts with other ions and molecules, or, by “stealing” an
electron from other molecules, to pair that electron. This
produces disruption to other molecules and damage to cells
[49]. One of the main problems is that ROS “steal” electrons
from lipid membranes (the cell membrane of most living
organisms is made of a lipid bilayer). The oxidative degrad-
ation of the lipid membrane is referred to as lipid peroxi-
dation. Lipid peroxidation results in loss of membrane
integrity and fluidity, which ultimately leads to cell death
[50,51]. ROS also react with proteins and nucleic acids
which can lead to cell death via apoptosis or necrosis [52].
Under normal conditions, a dynamic equilibrium exists
between the production of ROS and the antioxidant cap-
acity of the cell [53]. Oxidative stress occurs when there is
an imbalance between free radicals and the ability to
neutralize them (i.e. an excess of pro-oxidants, a decrease
in antioxidant levels, or both). The brain is highly vulner-
able to oxidative stress due to its limited antioxidant cap-
acity, higher energy requirement, and higher amounts of
lipids and iron [54].
In ASD, several post-mortem studies reveal that affected
areas of the brain in individuals diagnosed with an ASD
showed accelerated cell death under conditions of oxidative
stress [55-61]. For example, Lopez-Hurtado and Prieto [55]
found that the density of lipofuscin, a matrix of oxidized
lipid and cross-linked protein that forms as a result of oxi-
dative injury in the tissues, was observed to be greater in
cortical brain areas concerned with communication in indi-
viduals diagnosed with an ASD than in controls. As men-
tioned earlier, individuals diagnosed with an ASD typically
lose speech and language abilities at the time of regression.
Other studies have found elevated oxidative stress
markers in areas of the brain associated with ASD symp-
toms. Sajdel-Sulkowska et al [59]. reported that the brain
regions with the highest levels of the oxidative stress
marker, 3-nitrotyrosine (3-NT), were in the orbitofrontal
cortex, Wernicke's area, cerebellar vermis, cerebellar hemi-
sphere, and pons (brain areas associated with the speech
processing, sensory and motor coordination, emotional and
social behavior, and memory) in individuals diagnosed with
an ASD.
In two other studies by Sajdel-Sulkowska et al [57,58],
they found elevated 3-NT and neurotrophin-3 (NT-3),
markers of oxidative stress, in the cerebellum of individ-
uals diagnosed with an ASD in comparison with controls.
Evans et al [56] found elevated oxidative stress markers in
the brains of individuals diagnosed with an ASD by eva-
luating the oxidative stress metabolites of carboxyethyl
pyrrole (CEP) and iso[4]levuglandin (iso[4]LG)E2-protein
adducts in cortical brain tissues. These investigators re-
ported that the striking thread-like pattern appears to be a
hallmark in the brains of those diagnosed with an ASD, asit was not seen in any neurotypical brains, young or aged,
used as controls for the oxidative assays. Chauhan et al
[60] compared DNA oxidation and glutathione redox
status in postmortem brain samples from the cerebellum
and frontal, temporal, parietal and occipital cortex from
individuals diagnosed with an ASD and age-matched
neurotypical controls. These investigators reported that
DNA oxidation was significantly increased by two-fold in
the frontal cortex, temporal cortex, and cerebellum in in-
dividuals diagnosed with an ASD compared to controls.
Moreover, the levels of reduced glutathione were signifi-
cantly reduced, and the levels of oxidized glutathione were
significantly increased, in samples of the cerebellum and
temporal cortex from individuals diagnosed with an ASD
as compared to the corresponding levels in the control
brain samples. Earlier, Chauhan et al [61] found a signifi-
cant increase in the levels of lipid hydroperoxides, an oxi-
dative stress marker, in the cerebellum and temporal
cortex in individuals diagnosed with an ASD as compared
to controls.
8-oxo-guanosine (8oHdG) and neurodegeneration
8oHdG is an RNA oxidative damage marker that can be
used to assess oxidative stress that is found in the brain in
neurodegenerative disease [62]. Urinary 8OHdG has been
used successfully to measure brain damage and degener-
ation, showing a significant correlation (r = 0.87, p < 0.01)
with serum S100beta values, which are already used to
measure brain damage [63]. Sajdel-Sulkowska et al [58]
conducted a study where they examined oxidative damage
in the cerebellum of those individuals diagnosed with an
ASD by measuring 8OHdG. The authors found that cere-
bellar 8OHdG showed an upward trend toward higher
levels with an increase of 63.4% observed in those individ-
uals diagnosed with an ASD in comparison to controls.
Conclusion
To date, the etiology of ASD remains under debate.
There are, however, many studies that suggest toxicity in
children with ASD. A recent study conducted by the
Harvard School of Public Health [64], for example,
found that perinatal exposures to the highest versus lowest
quintile of diesel, lead, manganese, mercury, methylene
chloride, and an overall measure of metals were signifi-
cantly associated with ASD, with odds ratios ranging from
1.5 (for overall metals measure) to 2.0 (for diesel and mer-
cury). Similarly, Windham et al [65] examined possible as-
sociations between ASD and environmental exposures in
284 children with ASD and 657 controls, born in 1994
in the San Francisco Bay area. They found that the
individual compounds that contributed most to these
associations included mercury, cadmium, nickel, tri-
chloroethylene, and vinyl chloride, with the single lar-
gest risk factor being mercury. These findings that show
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larly mercury exposure, are corroborated by many other
studies [66-69]. In addition, studies show biomarkers of
susceptibility to toxins, such as reduced plasma and brain
tissue glutathione levels in ASD. Importantly, polymor-
phisms in glutathione-related genes modify mercury con-
centrations and antioxidant status in human subjects
environmentally exposed to mercury [70]. Yet, as men-
tioned earlier, the World Health Organization states that
ASD cannot be associated with toxic exposure because
there is no evidence of neurodegeneration in ASD.
However, the research examined in this critical review
provide compelling evidence for neurodegeneration as the
underlying mechanism for the loss of neurological func-
tion in individuals diagnosed with an ASD who have
regressed and lost previously acquired skills and abilities.
As with other neurodegenerative diseases, the evidence of
neurodegeneration in the brain in ASD includes: (1) neu-
ronal cell loss, (2) activated microglia and astrocytes, (3)
proinflammatory cytokines, (4) oxidative stress, and (5) el-
evated 8-oxo-guanosine levels. In addition, areas of the
brain that have shown evidence of neurodegeneration cor-
relate to areas known to be affected in ASD, including
areas of speech and socialization.
The current treatments of choice used in individuals di-
agnosed with an ASD include educational interventions
such as applied behavioral analysis (ABA) and/or psycho-
active drugs such as Risperdal. Neither of these types of
treatments addresses the apparently common issue of
neurodegeneration present in the brain of individuals diag-
nosed with an ASD. Future research should be undertaken
into treatments that address issues of neurodegeneration in
ASD. The evidence also suggests that regressive autism
should be included in the same category as other neurode-
generative diseases.
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